THE IMPORTANCE OF LIPID-SOLUBILITY FOR THE CENTRAL ACTION OF CHOLINOLYTIC DRUGS.
D001285:Atropine; D001535:Benactyzine; D001812:Blood-Brain Barrier; D001921:Brain; D018680:Cholinergic Antagonists; D004155:Diphenhydramine; D004569:Electroencephalography; D008055:Lipids; D051379:Mice; D009020:Morphine; D009966:Orphenadrine; D010276:Parasympatholytics; D010277:Parasympathomimetics; D010600:Pharmacology; D011680:Pupil; D011817:Rabbits; D051381:Rats; D012106:Research; D012601:Scopolamine; D012995:Solubility
D018680:Cholinergic Antagonists; D008055:Lipids; D010276:Parasympatholytics; D010277:Parasympathomimetics; D001535:Benactyzine; D009020:Morphine; D001285:Atropine; D004155:Diphenhydramine; D009966:Orphenadrine; D012601:Scopolamine
ATROPINE; BENACTYZINE; BLOOD-BRAIN BARRIER; BRAIN; DIPHENHYDRAMINE; ELECTROENCEPHALOGRAPHY; EXPERIMENTAL LAB STUDY; LIPIDS; MICE; MORPHINE; ORPHENADRINE; PARASYMPATHOLYTICS; PARASYMPATHOMIMETICS; PHARMACOLOGY; PUPIL; RABBITS; RATS; SCOPOLAMINE; SOLUBILITY